Since CD150 is not revealed in normal brain tissues but is expressed in 77.6% of CNS tumors, CD150 could be a novel diagnostic marker for CNS tumors and a potential target for the therapy of gliomas. The gene discussed is SLAMF1; the disease is central nervous system neoplasm.